Interactions between inhibitory molecules on T cells and their respective ligands on the leukemic cells/antigen-presenting cells investigated so far in ALL patients and in ALL murine models, include CTLA-4/CD80 or CD86, PD-1/PD-L1, TIM-3/galectin-9, TIGIT/CD155, and CD200/CD200R. Here, TIGIT is linked to acute lymphoblastic leukemia.